ARTASENSI, ANGELICA
ARTASENSI, ANGELICA
Dipartimento di Scienze Farmaceutiche
A Novel Chromatographic Method to Assess the Binding Ability towards Dicarbonyls
2023 A. Artasensi, E. Salina, L. Fumagalli, L. Regazzoni
Obesity and Type 2 Diabetes: Adiposopathy as a Triggering Factor and Therapeutic Options
2023 A. Artasensi, A. Mazzolari, A. Pedretti, G. Vistoli, L. Fumagalli
Evaluation of in vitro SARS-CoV-2 inactivation by a new quaternary ammonium compound: Bromiphen bromide
2023 S. Strizzi, G. Cappelletti, M. Biasin, A. Artasensi, L. Fumagalli, A. Casiraghi
Chemoenzymatic approach towards the synthesis of the antitumor and antileishmanial marine metabolite (+)-Harzialactone A via the stereoselective, biocatalyzed reduction of a prochiral ketone
2023 A. Artasensi, I. Bassanini, E. E Ferrandi, L. Feni, G. Vistoli, L. Fumagalli, R. Gandolfi
REPURPOSING AND MORPHING: A COMBINED STRATEGY TO DESIGN MULTI TARGET LIGANDS
2022 A. Artasensi
Discovery of a potent and highly selective Dipeptidyl Peptidase IV and Carbonic Anhydrase inhibitor as “antidiabesity” agent based on repurposing and morphing of WB-4101
2022 A. Artasensi, A. Angeli, C. Lammi, C. Bollati, S. Gervasoni, G. Baron, R. Matucci, C. Supuran, G. Vistoli, L. Fumagalli
Cyclo(His-Pro) Exerts Protective Carbonyl Quenching Effects through Its Open Histidine Containing Dipeptides
2022 L. Regazzoni, L. Fumagalli, A. Artasensi, S. Gervasoni, E. Gilardoni, A. Mazzolari, G. Aldini, G. Vistoli
Regioselective, Efficient and Sustainable Bromination Process for the Synthesis of the Antimicrobial Agent Bromiphen Bromide
2021 A. Artasensi, A. Pedretti, G. Vistoli, L. Fumagalli
Novel potential multitarget compounds for treatment of Type 2 Diabetes
2021 A. Artasensi, A. Angeli, C. Lammi, C. Supuran, G. Vistoli, L. Fumagalli
Candida albicans Biofilm Inhibition by Two Vaccinium macrocarpon (Cranberry) Urinary Metabolites: 5-(3',4'-{DihydroxyPhenyl})-gamma-Valerolactone and 4-Hydroxybenzoic Acid
2021 E. Ottaviano, G. Baron, L. Fumagalli, J. Leite, E.A. Colombo, A. Artasensi, G. Aldini, E. Borghi
Novel potential DPP IV/CA II inhibitors for treatment of type 2 diabetes
2021 A. Artasensi, A. Angeli, C. Lammi, C. Supuran, G. Vistoli, L. Fumagalli
Back to basics : choosing the appropriate surface disinfectant
2021 A. Artasensi, S. Mazzotta, L. Fumagalli
(Z)-5-(3′,4′-Bis(benzyloxy)benzylidene)furan-2(5H)-one
2021 A. Artasensi, G. Baron, G. Vistoli, G. Aldini, L. Fumagalli
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
2020 A. Artasensi, A. Pedretti, G. Vistoli, L. Fumagalli
Profiling Vaccinium macrocarpon components and metabolites in human urine and the urine ex-vivo effect on Candida albicans adhesion and biofilm-formation
2020 G. Baron, A. Altomare, L. Regazzoni, L. Fumagalli, A. Artasensi, E. Borghi, E. Ottaviano, C. Del Bo, P. Riso, P. Allegrini, G. Petrangolini, P. Morazzoni, A. Riva, L. Arnoldi, M. Carini, G. Aldini
Unexpected activity of bromiphen against prokaryotic and eukaryotic infectious agents
2019 L. Fumagalli, A. Artasensi, C. Picozzi, F. Sisto, E. Borghi, G. Bassanini, E. Ottaviano, G. Vistoli, M. Carini
How reaction conditions may influence the regioselectivity in the synthesis of 2,3-dihydro-1,4-benzoxathiine derivatives
2018 A. Casiraghi, E. Valoti, L. Suigo, A. Artasensi, E. Sorvillo, V. Straniero